Treatment-related toxicity of ML-DS 2006 patients. Percentage of ML-DS patients with severe adverse events (CTCAE grade III or higher) after each block of chemotherapy in comparison with the ML-DS patients, treated according to the AML-BFM 98 protocol. Only P values (Fisher exact) ≤.2 are shown. All other comparisons are P_FisherExact > .2. ALT, alanine transaminase; AST, aspartate transaminase.